Tesamorelin vs CJC-1295: Fat Loss or Muscle Growth?

Q: What is the difference between Tesamorelin and CJC-1295?

Tesamorelin is an FDA-approved synthetic version of GHRH (the hormone that triggers GH release), studied specifically for reducing deep belly fat. CJC-1295 is a research-grade GHRH analog with a much longer half-life, used for broader GH elevation including muscle and recovery goals.

Q: What is CJC-1295 with DAC versus without DAC?

DAC stands for Drug Affinity Complex, a modification that makes CJC-1295 bind to blood proteins and last for one to two weeks in the body. Without DAC, CJC-1295 has a half-life of about 30 minutes. The DAC version allows weekly dosing instead of daily injections.

Q: Can you stack Tesamorelin or CJC-1295 with a GHRP?

Yes. Both are GHRH analogs, which means they work well when paired with a growth hormone releasing peptide (GHRP) like Ipamorelin. The GHRH analog and GHRP act on different receptors and together produce a stronger GH release than either alone.

Built by medical professionals, gym rats, and experienced biohackers

Quick Answer

Tesamorelin is more specialized and better studied; CJC-1295 is more flexible but less proven. Tesamorelin is for people targeting deep belly fat, backed by FDA approval and clinical trials. CJC-1295 is for people who want broader, longer-lasting GH elevation for body composition and recovery.

Tesamorelin vs CJC-1295 is a comparison between two compounds that belong to the same family (both mimic a hormone called GHRH) but are built for different goals and have very different track records.

What Is Tesamorelin?

Tesamorelin is a lab-made version of GHRH (growth hormone releasing hormone), which is the natural signal your brain uses to tell the pituitary gland to release GH.

It is FDA-approved under the brand name Egrifta for reducing excess visceral fat (the deep belly fat around the organs) in adults with HIV-associated lipodystrophy . In clinical trials, it reduced visceral fat by 15 to 18% over 26 weeks .

The standard research dose is 2mg per day, injected under the skin (subcutaneously) . It has a short half-life of about 30 to 40 minutes but its GH-stimulating effect lasts longer.

What Is CJC-1295?

CJC-1295 is a synthetic GHRH analog designed to last longer in the body than natural GHRH. It comes in two versions that behave very differently.

CJC-1295 without DAC has a half-life of about 30 minutes, similar to tesamorelin. Research doses are 100 to 300mcg per injection, taken daily or multiple times per day .

CJC-1295 with DAC (Drug Affinity Complex) is modified to bind to blood proteins and stay active for one to two weeks . This allows once-per-week or twice-per-week dosing at around 1 to 2mg per week . The continuous GH elevation from the DAC version looks different on paper than the more pulsatile pattern from the non-DAC version.

CJC-1295 is a research compound with no FDA approval.

How Do Tesamorelin and CJC-1295 Differ?

Feature	Tesamorelin	CJC-1295 (no DAC)	CJC-1295 with DAC
Mechanism	GHRH analog	GHRH analog	GHRH analog, albumin-binding
FDA approval	Yes (HIV lipodystrophy)	No	No
Half-life	30 to 40 min	30 min	1 to 2 weeks
Typical research dose	2mg/day	100 to 300mcg/injection	1 to 2mg/week
Primary studied use	Visceral fat reduction	GH pulse support	Sustained GH elevation
Evidence level	High (randomized human trials)	Low (limited human data)	Low (limited human data)
Common side effect	Fluid retention, injection site reactions	Fluid retention	Sustained fluid retention possible

Mechanism

Both compounds work the same way at a high level: they bind to the GHRH receptor and signal the pituitary to release GH. What makes them different is duration and specificity.

Tesamorelin is a close copy of natural GHRH. It acts, then clears. CJC-1295 with DAC stays in the bloodstream for days to weeks, which means GH elevation is more continuous. Whether continuous or pulsatile GH is better for any given goal is still a matter of debate in the research community .

Evidence Level

Tesamorelin has strong human clinical trial data. CJC-1295 has much weaker human evidence. Most CJC-1295 data comes from animal studies or small, early-phase human trials .

Can You Stack Either with a GHRP?

Yes, and this is common. Both tesamorelin and CJC-1295 are GHRH analogs. They work on a different receptor than GHRPs (like Ipamorelin). When used together, a GHRH analog and a GHRP can produce a stronger GH release than either alone .

The CJC-1295 plus Ipamorelin combination is one of the most widely discussed peptide stacks in the research community. Tesamorelin can also be paired with a GHRP but this is less commonly discussed because tesamorelin is already well-studied alone.

If you are juggling multiple compounds on different schedules, DoseVault gives you a single place to track each one and log how your body is responding over time.

Which Do People Pick, and When?

This is general guidance, not personalized medical advice.

People tend to choose Tesamorelin when:
- Visceral fat (deep belly fat) is the primary goal
- They want a compound with actual FDA approval and human clinical trial data
- They are working with a physician who can prescribe it

People tend to choose CJC-1295 (without DAC) when:
- They want a flexible GHRH compound to combine with a GHRP like Ipamorelin
- They are comfortable with daily injections and want pulsatile GH patterns

People tend to choose CJC-1295 with DAC when:
- They want convenience of once-per-week dosing
- They are focused on sustained GH elevation for general body composition and recovery goals

Newcomers often start with the simpler daily non-DAC version before considering the longer-acting DAC form.

Frequently Asked Questions

What is the difference between Tesamorelin and CJC-1295?
Tesamorelin is an FDA-approved GHRH analog studied specifically for visceral fat reduction. CJC-1295 is a research-grade GHRH analog with a longer half-life, used for broader GH elevation.

Is Tesamorelin FDA-approved?
Yes. Tesamorelin is FDA-approved under the brand name Egrifta for reducing excess visceral fat in adults with HIV-associated lipodystrophy. Outside that use, it is a research compound.

What is CJC-1295 with DAC versus without DAC?
DAC (Drug Affinity Complex) is a modification that extends CJC-1295's half-life from 30 minutes to one to two weeks. The DAC version is dosed weekly; the non-DAC version is dosed daily.

Can you stack Tesamorelin or CJC-1295 with a GHRP?
Yes. Both are GHRH analogs that pair well with GHRPs like Ipamorelin. Together, they act on different receptors and can produce a stronger combined GH release than either alone.

Disclaimer

This page is for educational purposes only and is not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. CJC-1295 has no FDA approval for any use. Do not start any peptide protocol without guidance from a licensed healthcare provider. Consult a qualified clinician before using either compound.

Ready to track your protocol? DoseVault is built to help you log doses, timing, and how your body responds across every compound in your stack.

Built by medical professionals, gym rats, and experienced biohackers